Following Eli Lilly and Johnson & Johnson, Sanofi is aiming to change how it participates in the 340B program, a federal drug pricing program created in 1992, The Wall Street Journal reported Nov. 22.
As federal scrutiny and legislative proposals continue around the 340B drug pricing program, health systems are stepping up advocacy efforts and preparing for potential disruptions. At St. Louis-based ...
On October 30, HRSA announced that it had selected eight drug manufacturers to participate in its 340B Rebate Model Pilot Program, spanning 10 drugs representing a range of widely used therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results